



12-29-04

09/927,285

COFC
\$

Express Mail Label No.

Dated: _____

Docket No.: 04168/100J672-US2
(PATENT)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Letters Patent of:
Jian-Qiang Fan et al.

Patent No.: 6,774,135 **B2**

Issued: August 10, 2004

For: METHOD OF ENHANCING LYSOSOMAL α -
GALACTOSIDASE A

REQUEST FOR CERTIFICATE OF CORRECTION
PURSUANT TO 37 CFR 1.322

ATTN: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate
JAN 0 5 2005
of Correction

Dear Sir:

Upon reviewing the above-identified patent, Patentee noted errors which should be corrected.

Claims 4-6 and 10-12

4-6 and 10-12 (previously numbered claims 13-15 and 19-20 in the corresponding application), the word "cell" should be inserted following the word "mammalian." This was a simple clerical error wherein the word was inadvertently omitted. The claims currently read, "A method of enhancing the activity of lysosomal α -galactosidase A in a *mammalian* comprising administering an effective amount of a compound..." Support for the correction is found within the specification at column 2, lines 27-29, which states, "It is a further object of the invention to provide a method of enhancing α -Gal A activity in mammalian cells, particularly in human cells."

01/03/2005 HLE444 00000193 6774135

01 FC:1811

100.00 OP

{W:\04168\100J672US2\00281484.DOC [REDACTED] }

JAN 0 6 2005

Therefore, no new matter has been introduced, and there was no deceptive intent on the part of the Applicant.

Claim 4

In issued claim 4 (previously numbered claim 13) in column 12, text line 45, the claim reads "...wherein R₁ represents H; CH₃, or CH₂CH₃; and..." The first semicolon should be a comma. This correction not add new matter, since the Applicant listed the claim with the comma in the Amendment dated December 2, 2003 filed in response to the Office Action dated June 2, 2003 (Tab A). The previously numbered claim 13 was subsequently allowed in the Notice of Allowance dated December 31, 2003 (Tab B) and was issued as claim 4.

Claims 21- 23

Claims 21 and 23 contain a duplicated phrase which is not necessary. It recites that a method "*comprising administering an effective amount of a compound comprising administering an effective amount of a compound...*" One of these phrases should be removed so the claim recites this phrase only one time.

Claim 22 recites a method "*comprising administering an effective amount of a calystegine compound comprising administering an effective amount of compound...*" The former phrase, which references the calystegine compound, should be removed.

These errors were inadvertent and not made with deceptive intent.

Claims 34-36

Within the second line of each of issued claims 34-36, "a typical" should be replaced with the word "atypical". The Amendment dated December 2, 2003 (Tab A) recites the claims (previously numbered 43, 44, and 45, respectively) correctly. Thus, no new matter has been introduced.

Transmitted herewith are:

- (1) a copy of the above identified Amendment and Express Mail Certificate; and
- (2) a proposed Certificate of Correction Form PTO/SB/44 effecting the necessary Amendment; and
- (3) the requisite fee.

The Commissioner is hereby authorized to charge any deficiency or credit any overpayment in fees to Darby & Darby Deposit Account No. 04-0100.

Patentee respectfully solicits the granting of the requested Certificate of Correction.

Dated: December 27, 2004

Respectfully submitted,

By Stephanie R. Amoroso, Ph.D.

Registration No.: 51,401
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 753-6237 (Fax)
Attorneys/Agents For Applicant

JAN 06 2005



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/927,285	
	Filing Date	August 10, 2001
	First Named Inventor	Jian-Qiang Fan
	Art Unit	1623
	Examiner Name	M. C. Henry
Attorney Docket Number	04168/100J672-US2	
Total Number of Pages in This Submission		

ENCLOSURES (Check all that apply)


<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Request for Certificate of Correction; Exhibit Tabs A-B; Certificate of Express Mailing; and Return Receipt Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	DARBY & DARBY P.C.		
Signature			
Printed name	Stephanie R. Amoroso, Ph.D.		
Date	December 27, 2004	Reg. No.	51,401

Express Mail Label No.

Dated: _____



Application No. (if known): 09/927,285

Attorney Docket No.: 04168/100J672-US2

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. _____ in an envelope addressed to:

EV382053748-US

MS Post Issue
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on December 27, 2004
Date

Signature

Typed or printed name of person signing Certificate

Registration Number, if applicable

(212) 527-7700
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Request for Certificate of Correction (3 pages);
Certificate of Correction (2 pages)
Exhibit Tabs A-B
Fee Transmittal (1 page)
Transmittal Form (1 page)
Check in the amount of \$100.00
Return Receipt Postcard



Application No. (if known): 09/927,285

Attorney Docket No.: 04168/100J672-US2

Express Mail Certificate Under 37 CFR §1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Airbill No. _____ in an envelope addressed to:

E 982102706-us

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on December 2, 2003
Date

D. Davis
Signature
D. Davis

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Amendment (15 pages);

Terminal Disclaimer (1 page);


Amendment Fee Transmittal (1 page);

Petition And Extension of Time (1 page);

Fee Transmittal (1 page);

Check in the amount of \$ 1432.00 and CHECK # 3434

Postcard



Name (Print) _____


Signature

Customer No.: 07278


{W:\04168\100J672-US1\00095495.DOC 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 }

Please cancel claims 1-9. Please add new claims 10-48 as follows:


10. (new) A method of treating Fabry disease comprising administering to an individual in need thereof an effective amount of a compound of the formula:



11. (new) A method of treating Fabry disease comprising administering to an individual in need thereof an effective amount of a compound of the formula:




12. (new) A method of treating Fabry disease comprising administering to an individual in need thereof an effective amount of a compound of the formula:




wherein R_1 represents H, CH_3 , or CH_2CH_3 ;
 R_2 and R_3 independently represent H, OH, a 1-6 carbon alkyl, hydroxyalkyl, alkoxy, or a simple sugar; and
 R_4 and R_5 independently represent H or OH.

13. (new) A method of enhancing the activity of lysosomal α -galactosidase A in a mammalian comprising administering an effective amount of a compound of the formula:




wherein R_1 represents H, CH_3 , or CH_2CH_3 ; and
 R_2 and R_3 independently represent H, OH, a simple sugar, a 1-3 carbon alkyl, alkoxyl, or hydroxyalkyl group.

14. (new) A method of enhancing the activity of lysosomal α -galactosidase A in a mammalian comprising administering an effective amount of a compound of the formula:



wherein
 for calystegine A₃: R₁ = H, R₂ = OH, R₃ = H, R₄ = H;
 for calystegine B₂: R₁ = H, R₂ = OH, R₃ = H, R₄ = OH;
 for calystegine B₃: R₁ = H, R₂ = H, R₃ = OH, R₄ = OH; and
 for N-methyl-calystegine: R₁ = CH₃, R₂ = OH, R₃ = H, R₄ = H.


15. (new) A method of enhancing the activity of lysosomal α -galactosidase A in a mammalian comprising administering an effective amount of a compound of the formula:



wherein
 R₁ represents H, CH₃, or CH₂CH₃;
 R₂ and R₃ independently represent H, OH, a 1-6 carbon alkyl, hydroxyalkyl, alkoxy, or a simple sugar; and
 R₄ and R₅ independently represent H or OH.


16. (new) A method of stabilizing lysosomal α -galactosidase A in mammalian cells comprising administering an effective amount of a compound of formula:

16. (new) A method of stabilizing lysosomal α -galactosidase A in mammalian cells comprising administering an effective amount of a compound of formula:



wherein R₁ represents H, CH₃, or CH₂CH₃; and
R₂ and R₃ independently represent H, OH, a simple sugar, a 1-3 carbon alkyl, alkoxyl, or hydroxyalkyl group.

17. (new) A method of stabilizing lysosomal α -galactosidase A in mammalian cells comprising administering an effective amount of a compound of formula:



wherein


for calystegine A₃: R₁ = H, R₂=OH, R₃=H, R₄=H;

for calystegine B₂: R₁ = H, R₂=OH, R₃=H, R₄=OH;

for calystegine B₃: R₁ = H, R₂=H, R₃=OH, R₄=OH; and


for N-methyl-calystegine: R₁ = CH₃, R₂=OH, R₃=H, R₄=H.

18. (new) A method of stabilizing lysosomal α -galactosidase A in mammalian cells comprising administering an effective amount of a compound of formula:




wherein R_1 represents H, CH_3 , or CH_2CH_3 ;
 R_2 and R_3 independently represent H, OH, a 1-6 carbon alkyl, hydroxyalkyl, alkoxy, or a simple sugar; and
 R_4 and R_5 independently represent H or OH.

19. (new) A method of preventing the degradation of lysosomal α -galactosidase A in a mammalian comprising administering an effective amount of a compound of the formula:



wherein R_1 represents H, CH_3 , or CH_2CH_3 ; and
 R_2 and R_3 independently represent H, OH, a simple sugar, a 1-3 carbon alkyl, alkoxy, or hydroxyalkyl group.


20. (new) A method of preventing the degradation of lysosomal α -galactosidase A in a mammalian comprising administering an effective amount of a compound of the formula:



wherein for calystegine A₃: $R_1 = H$, $R_2 = OH$, $R_3 = H$, $R_4 = H$;
for calystegine B₂: $R_1 = H$, $R_2 = OH$, $R_3 = H$, $R_4 = OH$;
for calystegine B₃: $R_1 = H$, $R_2 = H$, $R_3 = OH$, $R_4 = OH$; and

for N-methyl-calystegine: $R_1 = \text{CH}_3$, $R_2 = \text{OH}$, $R_3 = \text{H}$, $R_4 = \text{H}$.

21. (new) A method of preventing the degradation of lysosomal α -galactosidase A in a mammalian comprising administering an effective amount of a compound of the formula:




wherein R_1 represents H, CH_3 , or CH_2CH_3 ;

R_2 and R_3 independently represent H, OH, a 1-6 carbon alkyl, hydroxyalkyl, alkoxy, or a simple sugar; and

R_4 and R_5 independently represent H or OH.


22. (new) A method of preventing deposition of neutral glycosphingolipids in vascular endothelial cells in an individual in need thereof, comprising administering an effective amount of a compound of formula:



wherein R_1 represents H, CH_3 , or CH_2CH_3 ; and

R_2 and R_3 independently represent H, OH, a simple sugar, a 1-3 carbon alkyl, alkoxy, or hydroxyalkyl group.

23. (new) A method of preventing deposition of neutral glycosphingolipids in vascular endothelial cells in an individual in need thereof, comprising administering an effective amount of a calystegine compound of formula:



wherein


for calystegine A₃: R₁ = H, R₂=OH, R₃=H, R₄=H;

for calystegine B₂: R₁ = H, R₂=OH, R₃=H, R₄=OH;

for calystegine B₃: R₁ = H, R₂=H, R₃=OH, R₄=OH; and

for N-methyl-calystegine: R₁ = CH₃, R₂=OH, R₃=H, R₄=H.

24. (new) A method of preventing deposition of neutral glycosphingolipids in vascular endothelial cells in an individual in need thereof, comprising administering an effective amount of a compound of formula:



wherein R₁ represents H, CH₃, or CH₂CH₃;
R₂ and R₃ independently represent H, OH, a 1-6 carbon alkyl, hydroxyalkyl, alkoxy, or a simple sugar; and
R₄ and R₅ independently represent H or OH.

25. (new) The method of claim 24, wherein the compound is selected from the group consisting of 1-deoxynojirimycin, 1-deoxygalactonojirimycin, α -homonojirimycin, 3,4-diepi- α -homonojirimycin, and 4-*epi*-fagomine.


26. (new) The method of claim 25 wherein the compound is 1-deoxygalactonojirimycin.

27. (new) The method of claim 22, wherein the glycosphingolipids are predominantly ceramide trihexoside.

28. (new) The method of claim 23, wherein the glycosphingolipids are predominantly ceramide trihexoside.


29. (new) The method of claim 24, wherein the glycosphingolipids are predominantly ceramide trihexoside.

30. (new) A method of preventing renal failure associated with deposition of neutral glycosphingolipids in vascular endothelial cells in an individual in need thereof, comprising administering an effective amount of a compound comprising administering an effective amount of a compound of formula:




wherein R₁ represents H, CH₃, or CH₂CH₃; and
R₂ and R₃ independently represent H, OH, a simple sugar, a 1-3 carbon alkyl, alkoxyl, or hydroxy-alkyl group.

31. (new) A method of preventing renal failure associated with deposition of neutral glycosphingolipids in vascular endothelial cells in an individual in need thereof, comprising administering an effective amount of a calystegine compound comprising administering an effective amount of a compound of formula:



wherein for calystegine A₃: R₁ = H, R₂ = OH, R₃ = H, R₄ = H;
 for calystegine B₂: R₁ = H, R₂ = OH, R₃ = H, R₄ = OH;
 for calystegine B₃: R₁ = H, R₂ = H, R₃ = OH, R₄ = OH; and
 for N-methyl-calystegine: R₁ = CH₃, R₂ = OH, R₃ = H, R₄ = H.

32. (new) A method of preventing renal failure associated with deposition of neutral glycosphingolipids in vascular endothelial cells in an individual in need thereof, comprising administering an effective amount of a compound comprising administering an effective amount of a compound of formula:



wherein R₁ represents H, CH₃, or CH₂CH₃;
 R₂ and R₃ independently represent H, OH, a 1-6 carbon alkyl, hydroxyalkyl, alkoxy, or a simple sugar; and
 R₄ and R₅ independently represent H or OH.

33. (new) The method of claim 32, wherein the compound is selected from the group consisting of 1-deoxynojirimycin, 1-deoxygalactonojirimycin, α -homonojirimycin, , 3,4-diepi- α -homonojirimycin, and 4-*epi*-fagomine.


34. (new) The method of claim 33 wherein the compound is 1-deoxygalactonojirimycin.

35. (new) The method of claim 30, wherein the glycosphingolipids are predominantly ceramide trihexoside.

36. (new) The method of claim 31, wherein the glycosphingolipids are predominantly ceramide trihexoside.


37. (new) The method of claim 32, wherein the glycosphingolipids are predominantly ceramide trihexoside.

38. (new) A method of preventing premature myocardial infarctions and strokes associated with deposition of neutral glycosphingolipids in vascular endothelial cells in an individual in need thereof, comprising administering an effective amount of a compound of formula:




wherein R₁ represents H, CH₃, or CH₂CH₃; and
R₂ and R₃ independently represent H, OH, a simple sugar, a 1-3 carbon alkyl, alkoxyl, or hydroxy-alkyl group.

39. (new) A method of preventing premature myocardial infarctions and strokes associated with deposition of neutral glycosphingolipids in vascular endothelial cells in an individual in need thereof, comprising administering an effective amount of a compound of formula:



wherein
 for calystegine A₃: R₁ = H, R₂ = OH, R₃ = H, R₄ = H;
 for calystegine B₂: R₁ = H, R₂ = OH, R₃ = H, R₄ = OH;
 for calystegine B₃: R₁ = H, R₂ = H, R₃ = OH, R₄ = OH; and
 for N-methyl-calystegine: R₁ = CH₃, R₂ = OH, R₃ = H, R₄ = H.

40. (new) A method of preventing premature myocardial infarctions and strokes associated with deposition of neutral glycosphingolipids in vascular endothelial cells in an individual in need thereof, comprising administering an effective amount of a compound of formula:



wherein
 R₁ represents H, CH₃, or CH₂CH₃;
 R₂ and R₃ independently represent H, OH, a 1-6 carbon alkyl, hydroxyalkyl, alkoxy, or a simple sugar; and
 R₄ and R₅ independently represent H or OH.

41. (new) The method of claim 40, wherein the compound is selected from the group consisting of 1-deoxynojirimycin, 1-deoxygalactonojirimycin, α -homonojirimycin, 3,4-diepi- α -homonojirimycin, and 4-*epi*-fagomine.

42. (new) The method of claim 41 wherein the compound is 1-deoxygalactonojirimycin.

43. (new) The method of claim 38, wherein the individual has the atypical variant form of Fabry disease.

44. (new) The method of claim 39, wherein the individual has the atypical variant form of Fabry disease.

45. (new) The method of claim 40, wherein the individual has the atypical variant form of Fabry disease.

46. (new) The method of claim 38, wherein the glycosphingolipids are predominantly ceramide trihexoside.

47. (new) The method of claim 39, wherein the glycosphingolipids are predominantly ceramide trihexoside.

48. (new) The method of claim 40, wherein the glycosphingolipids are predominantly ceramide trihexoside.

REMARKS/ARGUMENTS

Claims 10-48 are pending in this application. Claims 1-9 have been canceled. New claims 10 are added.

Support for new claims 10-12 can be found in the specification on pages 4-5 and in Examples 9 and 10 on page 18, and in Figure 2B and Figure 11.

Support for new claims 13-15 can be found in the specification on pages 4-5, and in Figures and figure descriptions for Figure 2A, Figure 3A-B, Figure 4A-C, Figure 7, Figure 10 and Figure 11. Support can also be found in Examples 4 on pages 13-15 and Example 8 on page 17.

Support for new claims 16-18 can be found in the specification on pages 4-5 and in the figure description of Figure 6 on page 6, and also in Example 5 on page 16.

Support for new claims 19-21 can be found in the specification on page 3, second full paragraph.

Support for new claims 22-24, 27-32, and 35-48 can be found in the specification at page 1, first full paragraph under the section entitled BACKGROUND OF THE INVENTION, and on pages 4-5.

Support for new claims 25-26 and 33-34 can be found in the specification on pages 4-5 and in Examples 1-3 and in Figures 1A-C.

The examiner has rejected originally filed claims under the judicially created doctrine of obviousness-type double patenting for allegedly not being patentably distinct from the claims of commonly-owned U.S. Patent No. 6,274,597 to Fan et al. Although Applicants have canceled claims 1-9, new claims 10-21 are generic to, or claim similar subject matter as commonly-owned patents 6,274,597 and 6,583,158, and 6,599,919, to Fan et al. Accordingly, submitted here with is a terminal disclaimer over the above-identified patents, which should obviate any obviousness-type double patenting rejections.


Reconsideration and allowance of the claims is respectfully requested.

If the Examiner has any other issues or concerns, please contact the undersigned at the telephone number below.

Respectfully submitted,

Dated: June 11, 2003

By:



Stephanie Amoroso, Ph.D.

Reg. No. 51,401

Agent for Applicants

Darby & Darby P.C.
Post Office Box 5257
New York, NY 10150-5257
212-527-7700

Appl. No. 09/927,285
Amdt. Dated December 2, 2003
Reply to Office Action of June 2, 2003



UNITED STATES PATENT AND TRADEMARK OFFICE

Stephanie B. Amoroso

Publ. fee

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov



NOTICE OF ALLOWANCE AND FEE(S) DUE

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022

12/31/2003

DUE: March 31, 2004Docketed on 1/6 by DP forDocketed without file ☐Attorney SEA

EXAMINER

HENRY, MICHAEL C

ART UNIT

PAPER NUMBER

1623

DATE MAILED: 12/31/2003

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/927,285	08/10/2001	Jian-Qiang Fan	2420/1J672US2	6863

TITLE OF INVENTION: METHOD OF ENHANCING LYSOSOMAL ALPHA-GALACTOSIDASE A

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330 ✓	\$300 ✓	\$1630	03/31/2004

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.

☐ Applicant claims SMALL ENTITY status.
See 37 CFR 1.27.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/927,285	08/10/2001	Jian-Qiang Fan	2420/1J672US2	6863

7590 12/31/2003
DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022



EXAMINER

HENRY, MICHAEL C

ART UNIT PAPER NUMBER

1623

DATE MAILED: 12/31/2003

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 144 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 144 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (703) 305-1383. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,774,135 *B2*
DATED : August 10, 2004
INVENTOR(S) : Jian-Qiang Fan; Satoshi Ishii

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 4, line 2; insert the word "cell" in front of the word "mammalian."

Claim 4, at line 46: replace the first semicolon with a comma to read -- wherein R₁ represents H, CH₃, or CH₂CH₃; and --.

Claim 5, line 2; insert the word "cell" in front of the word "mammalian."

Claim 6, line 2; insert the word --cell-- in front of the word "mammalian."

Claim 10, line 2; insert the word --cell-- in front of the word "mammalian."

Claim 11, line 2; insert the word --cell-- in front of the word "mammalian."

Claim 12, line 2; insert the word --cell-- in front of the word "mammalian."

Claim 21: delete the first instance of the following --comprising administering an effective amount of a compound --

Claim 22: delete the phrase --administering an effective amount of a calystegine compound--

Claim 23: delete the first instance of the following --comprising administering an effective amount of a compound --

MAILING ADDRESS OF SENDER:
Stephanie R. Amoroso, Ph.D.
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257

PATENT NO.: 6,774,135 *B2*

No. of additional copies: 1

JAN 06 2005

Claim 34, line 2; replace "a typical" with -- atypical --.

Claim 35, line 2; replace "a typical" with -- atypical --.

Claim 36, line 2; replace "a typical" with -- atypical --.

MAILING ADDRESS OF SENDER:

Stephanie R. Amoroso, Ph.D.

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

PATENT NO.: 6,774,135 B2

No. of additional copies: 1

JAN 06 2005